In the treatment of tumors, a commonly adopted immunotherapy strategy is to block the signaling of LILRB4 by inhibiting its association with its ligands such as APOE/FN using mAbs or inhibitors against LILRB4, thereby preventing the invasion and migration of tumor cells and restoring the immune effector activity of immune cells. The gene discussed is FN1; the disease is neoplasm.